Medicure Inc (MPH) - Total Assets

Latest as of March 2026: CA$23.38 Million CAD ≈ $16.91 Million USD

Based on the latest financial reports, Medicure Inc (MPH) holds total assets worth CA$23.38 Million CAD (≈ $16.91 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check Medicure Inc cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.

Medicure Inc - Total Assets Trend (2000–2025)

This chart illustrates how Medicure Inc's total assets have evolved over time, based on quarterly financial data. Explore long-term investment intensity of Medicure Inc to see how much of total assets are deployed in long-term investments.

Medicure Inc - Asset Composition Analysis

Current Asset Composition (December 2025)

Medicure Inc's total assets of CA$23.38 Million consist of 47.7% current assets and 52.4% non-current assets.

Asset Category Amount (CAD) % of Total Assets
Cash & Equivalents CA$0.00 15.4%
Accounts Receivable CA$4.72 Million 18.9%
Inventory CA$2.94 Million 11.8%
Property, Plant & Equipment CA$0.00 0.0%
Intangible Assets CA$7.75 Million 31.1%
Goodwill CA$4.26 Million 17.1%

Asset Composition Trend (2000–2025)

This chart illustrates how Medicure Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Medicure Inc market capitalisation.

Key Asset Composition Facts

  • Current vs. Non-Current Assets: Medicure Inc's current assets represent 47.7% of total assets in 2025, a decrease from 91.5% in 2000.
  • Cash Position: Cash and equivalents constituted 15.4% of total assets in 2025, down from 85.4% in 2000.
  • Tangible vs. Intangible: Intangible assets (including goodwill) make up 48.0% of total assets, an increase from 0.0% in 2000.
  • Asset Diversification: The largest asset category is intangible assets at 31.1% of total assets.

Medicure Inc Competitors by Total Assets

Key competitors of Medicure Inc based on total assets are shown below.

Company Country Total Assets
Swedish Orphan Biovitrum AB (publ)
ST:SOBI
Sweden Skr81.26 Billion
Aurobindo Pharma Limited
NSE:AUROPHARMA
India Rs585.02 Billion
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
China CN¥14.18 Billion
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858
China CN¥19.57 Billion
Tianjin Chase Sun Pharmaceutical Co Ltd
SHE:300026
China CN¥10.37 Billion
Zhejiang Hisoar Pharmaceutical Co Ltd
SHE:002099
China CN¥7.28 Billion
Xeris Pharmaceuticals Inc
NASDAQ:XERS
USA $392.01 Million
Procter & Gamble Health Limited
NSE:PGHL
India Rs8.94 Billion

Medicure Inc - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric Current 1 Year Ago 5 Years Ago
Current Ratio 1.04 1.71 1.27
Quick Ratio 0.73 1.29 0.86
Cash Ratio 0.00 0.00 0.00
Working Capital CA$392.00K CA$6.55 Million CA$3.01 Million

Medicure Inc - Advanced Valuation Insights

This section examines the relationship between Medicure Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio 0.86
Latest Market Cap to Assets Ratio 0.32
Asset Growth Rate (YoY) -15.9%
Total Assets CA$24.95 Million
Market Capitalization $8.08 Million USD

Valuation Analysis

Below Book Valuation: The market values Medicure Inc's assets below their book value (0.32x), which may indicate investor concerns about asset quality or future growth.

Significant Asset Reduction: Medicure Inc's assets decreased by 15.9% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.

Annual Total Assets for Medicure Inc (2000–2025)

The table below shows the annual total assets of Medicure Inc from 2000 to 2025.

Year Total Assets Change
2025-12-31 CA$24.95 Million
≈ $18.05 Million
-15.94%
2024-12-31 CA$29.68 Million
≈ $21.47 Million
+5.77%
2023-12-31 CA$28.06 Million
≈ $20.30 Million
-6.15%
2022-12-31 CA$29.90 Million
≈ $21.63 Million
+5.25%
2021-12-31 CA$28.41 Million
≈ $20.55 Million
-16.58%
2020-12-31 CA$34.05 Million
≈ $24.63 Million
-19.46%
2019-12-31 CA$42.28 Million
≈ $30.59 Million
-59.25%
2018-12-31 CA$103.76 Million
≈ $75.06 Million
-19.52%
2017-12-31 CA$128.93 Million
≈ $93.27 Million
-39.96%
2016-12-31 CA$214.73 Million
≈ $155.33 Million
+910.15%
2015-12-31 CA$21.26 Million
≈ $15.38 Million
+224.01%
2014-12-31 CA$6.56 Million
≈ $4.75 Million
+81.85%
2013-12-31 CA$3.61 Million
≈ $2.61 Million
+5.37%
2012-12-31 CA$3.42 Million
≈ $2.48 Million
-27.82%
2011-12-31 CA$4.74 Million
≈ $3.43 Million
-8.32%
2010-12-31 CA$5.17 Million
≈ $3.74 Million
-13.38%
2009-12-31 CA$5.97 Million
≈ $4.32 Million
-37.45%
2008-12-31 CA$9.55 Million
≈ $6.91 Million
-72.56%
2007-12-31 CA$34.81 Million
≈ $25.18 Million
-41.78%
2006-12-31 CA$59.79 Million
≈ $43.25 Million
+54.03%
2005-12-31 CA$38.81 Million
≈ $28.08 Million
+285.33%
2004-12-31 CA$10.07 Million
≈ $7.29 Million
-55.00%
2003-12-31 CA$22.39 Million
≈ $16.19 Million
+322.69%
2002-12-31 CA$5.30 Million
≈ $3.83 Million
-43.52%
2001-12-31 CA$9.38 Million
≈ $6.78 Million
+112.05%
2000-12-31 CA$4.42 Million
≈ $3.20 Million
--

About Medicure Inc

V:MPH Canada Drug Manufacturers - Specialty & Generic
Market Cap
$8.08 Million
CA$11.17 Million CAD
Market Cap Rank
#27558 Global
#1185 in Canada
Share Price
CA$1.07
Change (1 day)
+2.88%
52-Week Range
CA$0.90 - CA$1.43
All Time High
CA$10.58
About

Medicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies in the United States. The company markets AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary … Read more